Free Trial

Qiagen Q4 2024 Earnings Report

Qiagen logo
$39.69 -0.11 (-0.28%)
As of 03/25/2025 03:58 PM Eastern

Qiagen EPS Results

Actual EPS
$0.61
Consensus EPS
$0.60
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Qiagen Revenue Results

Actual Revenue
N/A
Expected Revenue
$518.54 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Qiagen Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Qiagen Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Qiagen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Qiagen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Qiagen and other key companies, straight to your email.

About Qiagen

Qiagen (NYSE:QGEN) NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

View Qiagen Profile

More Earnings Resources from MarketBeat